Substance / Medication

Netarsudil

SNOMED 781253004 UMLS C4535718

Overview

Active Ingredient

netarsudil

RxNorm CUI

1992864

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Ocular hypertension

Pigmentary glaucoma

Open-angle glaucoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

NCT07325240Phase 4Active Not Recruiting30 enrolled

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

NCT06449352Phase 4Completed100 enrolled

Rocklatan® Evaluation

NCT05283395Phase 4Completed136 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Topical Netarsudil in Childhood Glaucoma: A Systematic Review.

Shaikh Omar, Kuziez Lana, Saeedi Osamah J et al. · Curr Eye Res · 2025

PMID: 39749726Meta-Analysis

Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.

Lee Jong-Wook, Ahn Hyeon-Soo, Chang Jinho et al. · Korean J Ophthalmol · 2022

PMID: 35989070Meta-AnalysisFull text (PMC)

Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials.

Luo Nachuan, Jiang Xun, Hao Meiqi et al. · Front Med (Lausanne) · 2022

PMID: 35979215Meta-AnalysisFull text (PMC)

Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors).

Juneja Riddhima, Khan Taskin, Gupta Vishnu Swarup et al. · Int Ophthalmol · 2025

PMID: 40504269RCT

Comparison of Dorzolamide and Netarsudil on Intraocular Pressure and Ocular Perfusion in Early Glaucoma: A Randomized Controlled Trial.

Angmo Dewang, Jain Vanaja, Warjri Gazella Bruce et al. · J Glaucoma · 2025

PMID: 40719703RCT

Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension.

Shahid Saima, Rizvi Syed Wajahat A, Khan Adeeb A et al. · Indian J Ophthalmol · 2024

PMID: 38146971RCTFull text (PMC)

MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.

Stalmans Ingeborg, Lim Kin Sheng, Oddone Francesco et al. · Graefes Arch Clin Exp Ophthalmol · 2024

PMID: 37615697RCTFull text (PMC)

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).

Araie Makoto, Sugiyama Kazuhisa, Aso Kenji et al. · Adv Ther · 2023

PMID: 37603205RCTFull text (PMC)

Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.

Lindstrom Richard L, Lewis Amber E, Holland Edward J et al. · J Ocul Pharmacol Ther · 2022

PMID: 36327101RCTFull text (PMC)

Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.

Price Marianne O, Feng Matthew T, Price Francis W · Am J Ophthalmol · 2021

PMID: 33045216RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Netarsudil (substance)
SNOMED CT: 781253004
UMLS CUI: C4535718
RxNorm CUI: 1992864

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.